Abraxane (Paclitaxel Protein-Bound)

Overview

Abraxane is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer after other treatments have failed. Abraxane may be also referred to by its drug name…

Ado-Trastuzumab Emtansine

Overview
Ado-trastuzumab emtansine is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat some cases of HER2-positive, metastatic breast cancer. Ado-trastuzumab emtansine may be… read more

Afinitor (Everolimus)

Overview
Afinitor is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat advanced breast cancer in combination with exemestane after treatment with letrozole or anastrozole has failed.… read more

Arimidex (Anastrozole)

Overview
Arimidex is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer in postmenopausal women in cases where the cancer is early-stage and hormone receptor-positive,… read more

Aromasin (Exemestane)

Overview
Aromasin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) in 2005 to treat estrogen receptor-positive breast cancer after menopause. Aromasin is used as an adjuvant, or… read more

Beizray (Docetaxel) for Breast Cancer

Overview

Beizray is approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. It is indicated as a single agent for locally advanced or metastatic breast cancer after failure of previous…

Datroway (Datopotamab Deruxtecan-Dlnk)

Overview
Datroway is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with unresectable (not viable for surgery) or metastatic (advanced), hormone receptor (HR)-positive, human epidermal…

Ellence (Epirubicin hydrochloride)

Overview
Ellence is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with axillary node tumor involvement after removal of primary breast cancer. Ellence may be also referred… read more

Enhertu (Fam-trastuzumab deruxtecan-nxki)

Overview
Enhertu is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several types of breast cancer. It is indicated in combination with pertuzumab as a first-line treatment for adults with…

Fareston (Toremifene)

The Fareston brand name has been discontinued in the U.S. Other brand name or generic alternatives may be available.

Overview

Fareston is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to…

Faslodex (Fulvestrant)

Overview
Faslodex is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat estrogen receptor-positive breast cancer in postmenopausal women whose cancer progressed after treatment with… read more

Femara (Letrozole)

Overview
Femara is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat estrogen receptor-positive breast cancer in postmenopausal women. Femara is used as an adjuvant, or post-surgical,… read more

Gemzar (Gemcitabine)

Overview
Gemzar is approved by the U.S. Food and Drug Administration (FDA) for use in combination with the chemotherapy drug paclitaxel as a first-line treatment for metastatic breast cancer in individuals who have not…

Halaven (Eribulin mesylate)

Overview
Halaven is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in adults who have previously received two chemotherapy regimens. Halaven may be also… read more

Herceptin (Trastuzumab)

Overview
Herceptin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and one or more chemotherapy… read more

Herceptin Hylecta (Trastuzumab/Hyaluronidase-oysk)

Overview
Herceptin Hylecta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjuvant treatment for metastatic breast cancer in cases where tumors overexpress the HER2 protein and one… read more

Herzuma (Trastuzumab-Pkrb)

Overview
Herzuma is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer. It is prescribed for people with both early-stage and metastatic (cancer that has spread)…

Ibrance (Palbociclib)

Overview
Ibrance is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic breast cancer in combination with other medications. Ibrance is prescribed in cases where… read more

Infugem (Gemcitabine)

Overview
Infugem is approved by the U.S. Food and Drug Administration (FDA) for use in combination with paclitaxel as a first-line treatment for metastatic breast cancer. It is specifically used when previous…

Inluriyo (Imlunestrant)

Overview
Inluriyo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has…

Itovebi (Inavolisib)

Overview
Itovebi is approved by the U.S. Food and Drug Administration (FDA) for use in combination with palbociclib and fulvestrant to treat adults with hormone receptor (HR)-positive, human epidermal growth factor…

Ixempra (Ixabepilone)

Overview
Ixempra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic or locally advanced breast cancer after at least two other therapies have not worked. Ixempra may be… read more

Kadcyla (Ado-Trastuzumab Emtansine)

Overview
Kadcyla is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat some cases of HER2-positive, metastatic breast cancer. Kadcyla may be prescribed in cases where trastuzumab and a… read more

Kanjinti (Trastuzumab-Anns)

Overview
Kanjinti is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer. This medication is indicated for people with tumors that produce high levels of the HER2…

Keytruda (Pembrolizumab)

Overview
Keytruda is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with triple-negative breast cancer (TNBC). Keytruda is indicated to treat early-stage, high-risk TNBC… read more

Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph)

Overview
Keytruda Qlex is approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of triple-negative breast cancer (TNBC). It is approved for adults with high-risk early-stage TNBC in…

Kisqali (Ribociclib)

Overview
Kisqali is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an initial endocrine-based treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2… read more

Lynparza (Olaparib)

Overview
Lynparza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer. Lynparza may be prescribed for either hormone receptor-positive or -negative cases,… read more

Margenza (Margetuximab-cmkb)

Overview
Margenza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic HER2-positive breast cancer who have received two or more prior therapies. Margenza may… read more

Nerlynx (Neratinib)

Overview
Nerlynx is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as adjuvant (post-surgery) treatment for adults with early stage breast cancer in which HER2 is overexpressed or amplified.… read more

Ogivri (Trastuzumab-dkst)

Overview
Ogivri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer in cases where tumors overexpress the HER2 protein. Ogivri is also known by its drug name,… read more

Ontruzant (Trastuzumab-Dttb)

Overview
Ontruzant is approved by the U.S. Food and Drug Administration (FDA) for HER2-overexpressing breast cancer. Ontruzant is prescribed for both early-stage and metastatic HER2-positive breast cancer. Individuals are…

Orserdu (Elacestrant)

Overview
Orserdu is approved by the U.S. Food and Drug Administration (FDA) for treating postmenopausal women and adult men with estrogen receptor-positive (ER-positive), HER2-negative, ESR1-mutated advanced, or…

Perjeta (Pertuzumab)

Overview
Perjeta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and chemotherapy or anti-HER2 therapy… read more

Pertuzumab

Overview
Pertuzumab is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and chemotherapy or anti-HER2… read more

Phesgo (Pertuzumab, trastuzumab, and hyaluronidase-zzxf)

Overview
Phesgo is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) for use with chemotherapy to treat adults with early-stage HER-2 positive breast cancer. Phesgo is also approved… read more

Piqray (Alpelisib)

Overview

Piqray is a prescription medication approved by the Food and Drug Administration (FDA) to treat advanced or metastatic breast cancer in postmenopausal women. Piqray is also known by its drug name, Alpelisib.… read more

Soltamox (Tamoxifen Citrate)

Overview
Soltamox is approved by the U.S. Food and Drug Administration (FDA) for the treatment of estrogen receptor (ER)-positive metastatic breast cancer, as an adjuvant treatment for early-stage ER-positive breast…

Talzenna (Talazoparib)

Overview
Talzenna is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with HER2-negative and germline BRCA-mutated breast cancer that is metastatic or locally advanced.… read more

Tamoxifen

Overview
Tamoxifen is a prescription drug first approved by the U.S. Food and Drug Administration (FDA) in 1977 to treat breast cancer. Tamoxifen was later also approved to prevent breast cancer. Tamoxifen is commonly… read more

Taxotere (Docetaxel)

Overview
Taxotere is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat locally advanced or metastatic breast cancer after chemotherapy hasn’t worked. Taxotere is also approved to treat… read more

Trastuzumab

Overview
Trastuzumab is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and one or more chemotherapy… read more

Trazimera (Trastuzumab-Qyyp)

Overview
Trazimera is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer. Individuals who are eligible for Trazimera must have breast cancer that overexpresses…

Trodelvy (Sacituzumab govitecan-hziy)

Overview
Trodelvy is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic triple-negative breast cancer who have tried at least two other treatments.… read more

Truqap (Capivasertib)

Overview
Truqap is a prescription drug approved by the U.S. Food and Drug Administration (FDA) in combination with fulvestrant to treat some cases of hormone receptor (HR)-positive, human epidermal growth factor… read more

Tukysa (Tucatinib)

Overview
Tukysa is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with advanced inoperable or metastatic HER2+ breast cancer. Tukysa may be also referred to by its drug name,… read more

Tykerb (Lapatinib)

Overview
Tykerb is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in combination with capecitabine in cases where tumors overexpress the HER2 protein. The… read more

Verzenio (Abemaciclib)

Overview
Verzenio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat advanced or metastatic breast cancer. Verzenio may be prescribed in combination with Faslodex (fulvestrant), or… read more

Xeloda (Capecitabine)

Overview
Xeloda is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer. Xeloda may be prescribed either as monotherapy (on its own) in cases resistant to… read more

Zoladex (Goserelin Implant)

Overview
Zoladex is approved by the U.S. Food and Drug Administration (FDA) for the palliative treatment of advanced breast cancer in premenopausal and perimenopausal women, according to the prescribing information. This…